Sooyoung Lee

Mr. Sooyoung Lee

Kyung Hee University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SYSaebyul Yoo
Saebyul Yoo
BPBom-I Park
Bom-I Park
DKDo-Hyun Kim
Do-Hyun Kim
SLSooyoung Lee
Sooyoung Lee
SLSeung-Hoon Lee
Seung-Hoon Lee
BKBo-Hyung Kim
Bo-Hyung Kim
Red ginseng (RG) and black ginseng (BG, CJ EnerG) were prepared from fresh ginseng using one and nine cycles of steaming and drying, respectively. This process reduces the molecular weight (MW) of ginsenoside-active compounds in ginseng by removing sugar moieties from their dammaranes. We compared the pharmacokinetic characteristics of ginsenosides between BG comprising mainly low-MW ginsenosides (Rg3, Rg5, Rk1, and Rh1) and RG that predominantly contains high-MW ginsenosides (Rb1, Rb2, Rc, Rd, Re, and Rg1). The safety profiles and tolerability were also studied using a randomized, double-blind, single-dose, crossover clinical trial. A combination of Rb1, Rg1, and Rg3, well-known representative and functional RG components, exhibited a 1 h faster absorption rate (Tmax) and 58% higher exposure (24 h area under the concentration–time curve, AUC24) in BG than in RG. Furthermore, the combination of Rg3, Rg5, and Rk1, the major and most efficient components in BG, displayed 824% higher absorption (AUC24) in BG than in RG. The total ginsenoside showed a 5 h rapid intestinal absorption (Tmax) and 79% greater systemic exposure (AUC24) in BG than in RG. No clinically significant findings were observed in terms of safety or tolerability. Thus, BG extract was more effective than RG extract.

9 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SLSooyoung Lee
Sooyoung Lee
MSMOONSIK SONG
MOONSIK SONG
JHJongdae Han
Jongdae Han
DLDonghwan Lee
Donghwan Lee
BKBo-Hyung Kim
Bo-Hyung Kim
Bayesian therapeutic drug monitoring (TDM) software uses a reported pharmacokinetic (PK) model as prior information. Since its estimation is based on the Bayesian method, the estimation performance of TDM software can be improved using a PK model with characteristics similar to those of a patient. Therefore, we aimed to develop a classifier using machine learning (ML) to select a more suitable vancomycin PK model for TDM in a patient. In our study, nine vancomycin PK studies were selected, and a classifier was created to choose suitable models among them for patients. The classifier was trained using 900,000 virtual patients, and its performance was evaluated using 9000 and 4000 virtual patients for internal and external validation, respectively. The accuracy of the classifier ranged from 20.8% to 71.6% in the simulation scenarios. TDM using the ML classifier showed stable results compared with that using single models without the ML classifier. Based on these results, we have discussed further development of TDM using ML. In conclusion, we developed and evaluated a new method for selecting a PK model for TDM using ML. With more information, such as on additional PK model reporting and ML model improvement, this method can be further enhanced.

15 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMyeong-Bae Shin
Myeong-Bae Shin
SKSung-Ah Kim
Sung-Ah Kim
SLSooyoung Lee
Sooyoung Lee
WSWang Seob Shim
Wang Seob Shim
KLKyung-Tae Lee
Kyung-Tae Lee
BKBo-Hyung Kim
Bo-Hyung Kim
Fermentation of red ginseng (RG) produces fermented red ginseng (FRG), thereby increasing the relative amount of downstream ginsenosides, including compound Y (CY), F2, Rh2, compound K (CK), compound O, protopanaxadiol (PPD), and protopanaxatriol (PPT). These downstream ginsenosides have beneficial pharmacological effects, and are easily absorbed by the human body. Based on these expectations, a randomized, single-dose, two-period, crossover clinical trial was planned to compare the pharmacokinetic characteristics of seven types (Rb1, CY, F2, CK, Rh2, PPD, and PPT) of ginsenoside components after FRG and RG administration. The safety and tolerability profiles were assessed in this clinical trial. Sixteen healthy Korean male subjects were administered 6 g of FRG or RG. All ginsenosides except Rb1 showed higher systemic exposure after FRG administration than after RG administration, based on comparisons of ginsenoside Cmax and area under the concentration–time curve (AUC) between FRG and RG. CK, the main ginsenoside component produced during the fermentation process, had 69.23/74.53-fold higher Cmax/AUClast after administration of FRG than RG, and Rh2 had 20.27/18.47-fold higher Cmax/AUClast after administration of FRG than RG. In addition, CY and F2 were detected in FRG; however, all plasma concentrations of CY and F2, except in one subject, were below the lower limit of quantification in RG. There were no clinically significant findings with respect to clinical laboratory tests, blood pressures, or adverse events. Therefore, regular administration of FRG may exert better pharmacological effects than RG.

19 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SLSooyoung Lee
Sooyoung Lee
WSWang Seob Shim
Wang Seob Shim
HYHeejo Yoo
Heejo Yoo
SCSanghee Choi
Sanghee Choi
JYJiyoung Yoon
Jiyoung Yoon
KLKyung-Tae Lee
Kyung-Tae Lee
A sensitive and reproducible liquid chromatography-tandem mass spectrometry (LC-MS/MS) system was developed and fully validated for the simultaneous determination of ephedrine and pseudoephedrine in human plasma after oral administration of the herbal prescription Ojeok-san (OJS); 2-phenylethylamine was used as the internal standard (IS). Both compounds presented a linear calibration curve (r2 ≥ 0.99) over a concentration range of 0.2–50 ng/mL. The developed method was fully validated in terms of selectivity, lower limit of quantitation, precision, accuracy, recovery, matrix effect, and stability, according to the regulatory guidelines from the U.S. Food and Drug Administration and the Korea Ministry of Food and Drug Safety. This validated method was successfully applied for the pharmacokinetic assessment of ephedrine and pseudoephedrine in 20 healthy Korean volunteers administered OJS.

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
SLSooyoung Lee
Sooyoung Lee
SCSumin Chae
Sumin Chae
MKMinji Kwon
Minji Kwon
WSWang Seob Shim
Wang Seob Shim
KLKyung-Tae Lee
Kyung-Tae Lee
BKBo-Hyung Kim
Bo-Hyung Kim
Purpose: This study aimed to evaluate the pharmacokinetics and pharmacodynamics of metformin and Ojeok-san (OJS) co-administration to healthy volunteers compared to those with metformin alone. Methods: This was an open-label, one-sequence, crossover study, with two 2-day hospitalization schedules lasting up to 14 days. Metformin was administered once daily on days 1 and 2. OJS was administered alone three times a day on days 3– 7 and co-administered with metformin once a day on days 8 and 9. Plasma concentrations of metformin were measured using a validated LC-MS/MS method. To evaluate pharmacodynamics, oral glucose tolerance tests (OGTTs) were performed on days 1, 2, 8 and 9. Results: Fifteen participants were enrolled. The coadministration decreased Cmax (1757.7 to 1668.9 ng/mL) and AUClast (10407.4 to 9901.1 ng·h/mL), compared to those with metformin alone. Geometric mean ratios (90% Confidence Interval) of Cmax and AUClast between the co-administration with OJS and metformin alone were 92.15% (82.79– 102.57) and 94.57% (85.6– 104.48), respectively. Co-administration with OJS did not significantly change the mean glucose level compared to that with metformin alone. Conclusion: Co-administration with OJS decreased the plasma concentrations of metformin compared to that with metformin alone. However, the degree of decrease was not significant based on the geometric mean of the Cmax and AUClast. Considering the OGTT results, these changes in metformin concentration did not affect glucose concentration. In addition, there were no significant findings regarding safety profiles.

21 January 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SLSooyoung Lee
Sooyoung Lee
MSMOONSIK SONG
MOONSIK SONG
WLwoojae lim
woojae lim
ESEunjung Song
Eunjung Song
JHJongdae Han
Jongdae Han
BKBo-Hyung Kim
Bo-Hyung Kim
Most therapeutic drug monitoring (TDM) packages are based on the maximum a posteriori (MAP) estimation. In this study, HMCtdm, a new TDM package, was developed using a Hamiltonian Monte Carlo (HMC) simulation. The estimation process of HMCtdm for the drugs amikacin, vancomycin, theophylline, and phenytoin was based on the R package Torsten. The prior pharmacokinetic (PK) models of the drugs were derived from the Abbottbase® pharmacokinetics systems (PKS) program. The performance of HMCtdm for each drug was assessed through internal and external validations. The internal validation results of the HMCtdm were compared with those of a MAP-based estimation. The developed open-source HMCtdm package is user friendly. The validation results were reviewed and interpreted using the mean percentage error and root mean squared error. The successful transplantation of the prior PK structures (used in PKS) was confirmed by comparing the validation results with a MAP estimation. An open-source HMC-based TDM package was also successfully developed in this study, and its performance was evaluated. This package can be operated by users unfamiliar with C++ and can be further developed for various applications.